<DOC>
	<DOC>NCT01237223</DOC>
	<brief_summary>The purpose of the study was to evaluate the efficacy (blood pressure lowering effect) and safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in patients with essential hypertension (mean sitting diastolic blood pressure [msDBP] ≥ 95 mmHg and &lt; 110 mmHg and mean sitting systolic blood pressure [msSBP] ≥ 140 mmHg ). This study was conducted to support registration of the fixed-dose combination of aliskiren and amlodipine for the treatment of hypertension in Japan.</brief_summary>
	<brief_title>Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients with essential hypertension (msDBP ≥ 95 mmHg and &lt; 110 mmHg and msSBP ≥140 mmHg ) Outpatients Severe hypertension (msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg) History of allergy or hypersensitivity to renin inhibitors, calcium channel blockers History or evidence of a secondary hypertension Other protocoldefined inclusion/exclusion criteria applied</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Aliskiren</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>Essential hypertension</keyword>
</DOC>